DataMEDS AI Swings to $10.5M Q3 Profit on Debt Extinguishment; Revenue Up 50% Sequentially
MEDS sits 36% above its 52-week low of $0.553.
Summary
DataMEDS AI reported Q3 2026 revenue of $2.7 million, up 50% sequentially, and net income of $10.5 million driven almost entirely by a $19.1 million debt-extinguishment gain. The company also said it regained full Nasdaq compliance on October 19, 2026.
Key Events · Earnings and Guidance · MEDS
-
Q3 Revenue Up 50% Sequentially
Revenue was $2.7 million versus $1.8 million in Q2 2026, driven by Corexa Pharmacy drug dispensing, though still below the $3.0 million reported in Q3 2025.
-
Profit Is a Debt-Extinguishment Gain
Net income of $10.536 million included a $19.06 million gain on extinguishment of debt; the company actually ran a $3.37 million operating loss in the quarter.
-
Nasdaq Compliance Restored
The company said it regained full compliance with Nasdaq listing standards, including the net equity requirement, on October 19, 2026.
-
Equity Turns Positive
Stockholders' equity was $171,695 at September 30, 2026 versus a $12.45 million deficit at December 31, 2025, with cash of $476,598 against $37.9 million of current liabilities.
Analysis · MEDS · Trade & Services
The headline profit is accounting-driven, not operational: a $19.06 million gain on extinguishment of debt turned a $3.37 million operating loss into $10.54 million of net income. More important is the balance sheet. Stockholders' equity flipped from a $12.45 million deficit at year-end 2025 to $171,695 positive at September 30, 2026, and the company says it regained full Nasdaq compliance on October 19, 2026, removing the delisting risk flagged in the Q2 10-Q. Revenue of $2.7 million rose 50% sequentially but is still down from $3.0 million a year earlier, and cash of $476,598 against $37.9 million of current liabilities leaves little cushion. The HMO MOU covering 25,000+ members is non-binding, with definitive agreements only expected in Q4 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDS was trading at $0.75 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.55 to $35.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.